Shared on07 Aug 25Fair value Increased 8.97%
The consensus price target for Eris Lifesciences has been raised to ₹1852, reflecting improved expectations for both revenue growth and net profit margin. What's in the News Board meeting scheduled to approve standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.
Shared on24 Apr 25Fair value Decreased 6.25%
AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.
Shared on09 Apr 25Fair value Increased 1.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 5.69%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.